Abstract Submission Guidelines

 Abstract submission is now Closed

Please note, notifications to regular abstract submitters regarding the status of their abstract/s were sent at the end of June.

If you did not receive your notification, please contact us.

KEY DATES

*Note all efforts are made to send notification by the planned date. Should there be any delays with the selection process, revised date will be posted here

*Please note, there will be no extension to the deadline.

Guidelines for Late-Breaking Abstract Submission

• Abstracts containing high quality emerging data found between April 2, 2019 and September 3, 2019 should be submitted.
• Late-breaking abstracts will not be included in the official congress publications.
• Presenting authors must be registered participants.
• The content of the abstract should not have been previously published or presented at national or international meetings prior to SIOP 2019 and should be about:
  – prospective multicentric studies for which results were not known at the initial SIOP abstract deadline
  – important translational studies with emerging results
• A maximum of 3 abstracts will be selected by the SIOP scientific committee as late-breaking abstracts
• One Young investigator award may be attributed for one of them

Important Information

• Clinical Trials in Progress Abstracts cannot be submitted
• Shell Abstracts (abstracts that provide no data) cannot be submitted
• Previous Publications of an Abstract – an abstract can be submitted if it was/will be presented at a scientific meeting in the current year (2019). If it was presented in 2018, then it cannot be submitted unless there is significant new data.

Please follow the instructions listed on this website step-by-step:
1- Abstract Content 

• Prospective multicenter trials as well as presentation of large translational works are considered as major quality criteria. Inter-diseases sessions (such as target, pathway or immunology oriented) will be planned.
• Case reports and small institutional series of limited added scientific value are not encouraged.
• In general, the content of the abstract should not have been previously published or presented at national or international meetings. However, abstracts of prospective clinical trials may have been submitted /reported once in the calendar year of the congress but they cannot have been accepted for publication at time of abstract submission.

1-1 Abstract Topic 

Click here for the list of abstract topics.

1-2 Abstract Writing and Presentation 

• Abstracts must be submitted and presented in clear English with correct grammar and spelling of a quality suitable for publication. Please note that abstracts submitted with a low level of English will not be considered for presentation. Authors who would like assistance with the English writing of their abstract, should contact the Secretariat at least 2 weeks prior the deadline.
• Abstract title – Limited to 25 words in UPPER CASE
• Abstract text – Limited to 300 words. Including acknowledgements.
• We recommend using word-processing software (for example, Word) for editing your abstract and counting the number of words.
• Important Note: Abstracts submitted, which do not comply with the requirements/format below, will NOT be included in the journal publication.
• Abstracts must clearly state:
  • Background/Objectives
  • Design/Methods
  • Results
  • Conclusion
  • (Note: Each of the above sections must be a single paragraph and contain no lists). ​
• Abstract text must be written in complete sentences and in correct English.
• No degrees/titles of authors should be included with the author names.
• There should be a mark of end punctuation at the end of all sentences.
• Abbreviations must be consistent with instructions to authors of Pediatric Blood & Cancer and be defined on 1st usage, then use of abbreviation alone is OK, i.e. Wilms Tumor (WT), then referred to as “WT” in subsequent mention. Please use as few abbreviations as possible and only commonly used abbreviations.
• Disease names should be written without apostrophes, for example: Wilms tumour, Burkitt lymphoma, Hodgkin disease, etc.
• Please do not refer to patients by their diseases, e.g. ‘Wilms tumour patients’ or ALL patients’. Instead identify them as ‘patients with Wilms tumour; and ‘patients with ALL’.
• Use generic names of drugs.
• Express numbers as numerals.
• Text only is to be submitted. Tables, figures and bulleted text are not permitted.
• Numbers over 999 must include a comma, e.g., 2,000.
• Decimal points must be displayed as periods (4.89) not commas (4,89).
• Numbers beginning with a decimal point should be preceded by a zero.
• Periods should be used in numbers for decimal points, not commas, i.e. P=0.015
• All measurements must be in metric units.
• Do not begin sentences with a number – type the number in full, for example, it should be ‘Three patients….’ Instead of ‘3 patients….’.
• Do not use expressions such as ‘On the other hand……’; ‘This is the first study….’; ‘To our knowledge…..’; ‘This is the largest….’.
• Abstracts stating “data will be discussed in the presentation” will NOT be accepted.

2- Authorship 

• Submission of an abstract acknowledges your acceptance for the abstract to be published in the official congress publications.
• The same person may submit up to 5 abstracts regardless of presenting author. 
• The same person may serve as presenting author on up to 5 abstracts.
• The presenting author is required to ensure that all co-authors are aware of the content of the abstract and agree to its submission, before submitting the abstract.
• Presenting authors of abstracts must be registered participants. Registration must be received by the Secretariat by the Early Registration Deadline July 30, 2019 to ensure inclusion of the abstract in the meeting publications and in order to be scheduled for presentation.

3- Submission process 

• Abstracts must be submitted via the congress website. Abstracts submitted via fax will not be accepted.
• Recommended browser is Google Chrome or Mozilla
• Abstracts must be received by the announced deadline. Abstracts received after the deadline will not be considered.
• Abstract category – abstracts must be allocated to a specific category for the scientific programme. You will need to select the category most suited to your abstract. To preview the categories, please click here .

Preparation for Online Submission 

Before you start, please prepare the following information:

• Presenting author’s contact details
  • Email address
  • Full postal address
  • Daytime and evening phone number
• Author and co-authors’ details
  • Full first and family name(s)
  • Authors’ names must be in upper and lower case (John B Smith)
  • Affiliation details: department, institution / hospital, city, state (if relevant), country

Draft Abstracts 
By submitting the abstract it will be saved in draft status, to enable you to make changes/updates until the deadline. The abstract will be automatically submitted midnight, CET, on April 2, 2019.

Disclosure 
Disclosure of financial relationships that the author(s) may have with the manufacturer/supplier of any commercial products or services related to the work, should be indicated in the appropriate box on the abstract form.
​

Selection Process 
All abstracts will be evaluated anonymously and scored by the appropriate SPAC members.
Final decisions will be made by the Scientific Committee which will determine whether the abstract will be accepted or refused and if accepted, as:

• an oral presentation;
• a poster presentation, possibly with a poster session participation or special Scientific Committee mention;
• a journal publication, with consideration given to the author’s preference.